Cord Blood Expansion: Why Your Baby's Stem Cells Can Now Treat Adults

Cord blood has traditionally been a vital resource for treating children, but its limited cell count made it less practical for adults. Recent advancements in cord blood expansion now allow a single unit to be used for adult treatments by multiplying hematopoietic and mesenchymal stem cells in a lab. The FDA-approved Omisirge (April 2023) exemplifies this progress, reducing recovery times and expanding treatment options for conditions like blood cancers and severe aplastic anemia. With improved techniques and storage solutions, families can now bank cord blood as a long-term resource for treating a wide range of diseases across all ages.

Key Points:

• Cord blood expansion multiplies stem cells, making a single unit viable for adults.
• Omisirge reduces neutrophil recovery time from 22 to 12 days.
• Recent trials show a 94% survival rate for severe aplastic anemia patients.
• Expanded cord blood is being explored for regenerative medicine and conditions like Long COVID.
• Americord's CryoMaxx™ ensures high-quality storage for future treatments.

This advancement transforms cord blood into a versatile medical resource for families.

What Is Cord Blood Expansion and Why It's Important

Understanding Cord Blood Stem Cells

Cord blood is a rich source of hematopoietic stem cells (HSCs), which are identified by the CD34+ marker. These remarkable cells are responsible for producing red blood cells, white blood cells, and platelets. Collected at birth and stored in public vs private cord blood banking facilities, they are crucial for restoring the immune system and bone marrow, especially after medical treatments like chemotherapy.

Globally, more than 40,000 cord blood transplants have been performed, treating over 80 conditions such as blood cancers, immune deficiencies, and genetic disorders. However, HSCs are naturally scarce in cord blood, making up only about 0.02% to 1.43% of the total cells in a typical unit. This rarity underscores the importance of expanding these cells for broader therapeutic use.

Limitations of Traditional Cord Blood Use

While cord blood holds immense therapeutic promise, its limited cell count presents challenges - especially for adults. The effectiveness of a cord blood transplant depends on the recipient's body weight. A single cord blood unit typically contains enough stem cells to treat a child but falls short for most adults. To meet the required cell dose for larger patients, doctors often resort to double cord blood transplants, combining cells from two separate units. This workaround, while effective, is not ideal due to increased complexity and cost.

How Expansion Solves These Limitations

Cord blood expansion tackles these challenges by multiplying stem cells in a lab setting before transplantation. Scientists use growth factors or specialized molecules like nicotinamide (Vitamin B3) to culture the cells outside the body (ex vivo) for several weeks. This process can amplify CD34+ cell counts by 35-fold to an astonishing 1,594-fold, significantly increasing the total number of stem cells available.

This breakthrough means a single banked cord blood unit can now provide enough cells to treat an adult. Beyond that, expansion technologies improve the overall therapeutic potential of cord blood, turning it into a lifelong medical resource.

Feature	Standard Cord Blood	Expanded Cord Blood
Primary User	Children/Small Adults	Children and Adults (12+)
Cell Quantity	Directly collected	35–1,594× increase
Adult Viability	Often requires 2+ units	Single unit sufficient
Neutrophil Recovery	~21 days	~11.5 days

How Cord Blood Expansion Technologies Work

Ex Vivo Culturing and Bioreactors

The process begins with isolating CD34⁺ or CD133⁺ stem cells from a cord blood sample. These cells are then cultured ex vivo in specially designed nutrient-rich media enriched with growth factors. A "cytokine cocktail" - a mix of Stem Cell Factor (SCF), Thrombopoietin (TPO), and Flt-3 Ligand (FL) - is used to drive rapid cell expansion.

Bioreactors play a pivotal role here. Unlike traditional static systems like flasks or bags, bioreactors provide a dynamic environment. They continuously supply fresh nutrients and oxygen while clearing out waste and mature cells that could hinder stem cell growth. This setup mimics the natural bone marrow environment, optimizing conditions for cell proliferation.

"A continuous perfusion of culture medium that removed mature cells could protect the cultured cells from toxic byproducts." - SS Kelly, Department of Pediatrics, MD Anderson Cancer Center

Another key approach is stromal co-culture, where Mesenchymal Stem Cells are used to simulate bone marrow signals. For example, using the Notch ligand Delta1, researchers achieved a 164-fold expansion of CD34⁺ cells in just 16 days. The FDA-approved product Omidubicel (branded as Omisirge since April 17, 2023) delivers a median 130-fold expansion, while a small molecule called SR-1 can achieve up to a 330-fold expansion. These breakthroughs are paving the way for more effective treatments.

Advanced Techniques for Better Results

Modern techniques now focus on preventing premature stem cell maturation. Small molecules like Nicotinamide (Vitamin B3), SR-1, and UM171 target specific pathways to preserve the "primitive" state of stem cells. This ensures their ability to regenerate the blood system and sustain long-term engraftment.

In a 2023 Phase III trial involving 125 high-risk blood cancer patients, Nicotinamide-expanded cells showed remarkable results. Neutrophil engraftment occurred in just 12 days, compared to 22 days in the control group, significantly reducing the risk of infection during recovery.

Automation has also improved the process. Platforms like Sepax® ensure high yields with minimal contamination. Serum-free and feeder-free culturing methods, using specialized media like ImmunoCult™, reduce variability and eliminate risks tied to animal-derived products. Additionally, advanced cryopreservation techniques, such as ultra-rapid vitrification, prevent ice crystal formation during freezing, maintaining cell quality for long-term storage. Together, these advancements create a controlled and efficient environment for expanding cord blood, making it more viable for adult treatments.

Expansion Method	Key Technology	CD34⁺ Fold Expansion
Nicotinamide (Omidubicel)	Small Molecule (NAM)	130×
SR-1 (HSC835)	AHR Antagonist	330×
Notch Ligand	Delta1 Notch Ligand	164×
UM171	Pyrimidoindole derivative	28×
StemEx	Copper Chelator (TEPA)	77×

Medical Conditions Treated with Expanded Cord Blood in Adults

Blood and Genetic Disorders

Expanded cord blood is now used to treat blood cancers and bone marrow failure disorders such as Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Hodgkin's and Non-Hodgkin's Lymphoma, and Multiple Myeloma. It’s also effective for severe aplastic anemia, sickle cell disease, and beta thalassemia major in adults.

The FDA recently approved Omisirge for treating severe aplastic anemia in adults, following groundbreaking results from an NIH clinical trial led by Dr. Richard Childs. This study reported a 94% survival rate, with white blood cell recovery occurring in just 8 days - a significant milestone in hematopoietic stem cell transplant therapy.

"The results of this ongoing study are extremely encouraging and indicate a significant advancement in the treatment options for patients with a high unmet medical need." – Richard Childs, M.D., Assistant U.S. Surgeon General and NIH Study Lead

In another study conducted at Duke Cancer Institute in December 2018, Dr. Mitchell Horwitz treated 36 adults with blood cancers using NiCord (now Omisirge). The findings were remarkable - 94% of patients achieved engraftment within six weeks, much faster than historical benchmarks. Dr. Horwitz highlighted that this quicker recovery reduces risks during the most vulnerable post-transplant period, directly improving patient safety.

Beyond blood-related conditions, expanded cord blood is paving the way for advancements in regenerative medicine.

New Therapies in Regenerative Medicine

Clinical trials are exploring expanded cord blood's potential in treating neurological, autoimmune, and tissue injuries. By mid-2024, 36 trials were underway, investigating stem cell treatments for stroke, Parkinson's disease, spinal cord injuries, traumatic brain injuries, Type 1 diabetes, multiple sclerosis, and lupus.

In January 2026, the FDA approved an Expanded Access program for StemCyte’s RegeneCyte®, targeting Long COVID. Phase IIa trials showed that 85% of patients experienced significant relief from chronic fatigue, compared to just 20% in the placebo group. This program, led by CEO Dr. Tong-Young Lee, offers hope for patients with limited treatment options.

The regenerative power of expanded cord blood lies in its CD34+ cells, which produce elevated levels of neurotrophic factors (like BDNF and GDNF) and angiogenic factors (like VEGFA). These cells stimulate the body’s natural repair mechanisms rather than simply replacing damaged tissue. Promising research also indicates potential for muscle regeneration - animal studies revealed a 37.6% increase in gastrocnemius muscle weight after treatment with cord blood-derived exosomes.

These advancements highlight the long-term benefits of banking cord blood, ensuring its availability for a growing range of adult medical treatments.

Recent Advances Enabling Adult Treatments

Ex Vivo Expansion for Therapeutic Doses

Treating adults with stem cell therapies requires significantly larger doses than those used for children, but modern expansion technologies are making this possible.

One standout innovation is nicotinamide, a derivative of vitamin B3. It prevents stem cells from differentiating while multiplying in the lab, resulting in a 400-fold increase in total cells and an 80-fold increase in stem cells from just one cord blood unit. Another game-changing molecule, UM171, promotes stem cell self-renewal, achieving a 100-fold expansion in just one week. Meanwhile, SR-1 has shown the ability to expand CD34+ cells by an astounding 17,100-fold over five weeks, providing enough cells for even larger adult patients.

These chemical techniques don’t just increase the number of cells - they also maintain their quality and ability to engraft successfully. This ensures that the cells can rebuild a patient’s blood and immune system after a transplant. By combining quantity with quality, these advancements open the door to further medical progress.

AI and Clinical Improvements

Artificial intelligence is now playing a critical role in cord blood research and patient care. AI tools streamline research by identifying related therapeutic areas and using AI-trained oncology knowledge to help doctors determine which patients are most likely to benefit from expanded cord blood therapies.

On the manufacturing front, new three-stage expansion systems can produce up to 14 million tumor-killing natural killer (NK) cells from a single stem cell. This approach significantly reduces costs and minimizes the need for viral vectors - by as much as 1/140,000 to 1/600,000 compared to traditional methods. These advancements make personalized cell therapies more accessible and affordable for adult patients, setting the stage for broader clinical adoption.

FDA Approvals and Clinical Trials

Regulatory progress has been a key driver of adult stem cell therapy advancements. In April 2023, the FDA approved Omisirge (omidubicel-onlv) for patients 12 years and older with blood cancers. This therapy reduced median neutrophil recovery time from 22 days to just 12 days and shortened hospital stays from 61 to 48 days. By December 2025, its use expanded to include severe aplastic anemia in patients as young as six, with 12 out of 14 patients achieving engraftment in a median of 11 days.

"This approval is revolutionary in the therapeutic landscape and fundamentally changes how we approach treatment for SAA, where earlier treatment has potential to alter one's life course." – Vinay Prasad, M.D., M.P.H., Chief Medical and Scientific Officer, FDA's Center for Biologics Evaluation and Research

In November 2024, the FDA approved StemCyte's RegeneCyte for hematopoietic transplantation. Just two months later, in January 2026, the FDA launched an Expanded Access program allowing Long COVID patients to receive RegeneCyte while Phase III trials continue. Across the Atlantic, the European Commission granted conditional approval to Zemcelpro (UM171 Cell Therapy) in August 2025. This therapy provides a lifeline for adult blood cancer patients who lack matched donors.

These approvals underscore the growing recognition of expanded cord blood therapies as safe and effective solutions, backed by rigorous clinical data.

Why Bank with Americord Registry

Americord Registry offers a forward-thinking approach to stem cell preservation, ensuring that your baby's stem cells are stored in a way that maximizes their potential for future therapies.

CryoMaxx™ Processing for Expansion-Ready Storage

Americord's CryoMaxx™ technology tackles a key challenge in cord blood expansion: preserving enough high-quality stem cells. This proprietary method ensures 99% cell viability and recovers 2-3 times more nucleated cells compared to standard methods. It also maintains higher CD34+ cell counts, which are crucial for successful expansion.

The process involves advanced separation and density gradient techniques during collection and freezing. This means the cord blood retains more undamaged, primitive hematopoietic stem cells. When thawed for use in bioreactors, these cells expand more effectively, reaching the therapeutic levels needed for adult treatments. Since traditional cord blood units often lack enough cells for patients over 110 pounds, CryoMaxx™ ensures your stored stem cells are ready to meet future needs.

In addition to advanced processing, Americord offers flexible, long-term banking solutions tailored for families.

Family Banking Plans

Americord's family banking plans go beyond just cord blood storage. Starting at $3,499, these plans cover the collection and processing of both cord blood and cord tissue, with annual storage fees of $125. For families seeking a broader range of options, the Maximum Family Plan includes cord blood, cord tissue, placental tissue, and exosome banking for both newborns and mothers. This ensures access to a wider variety of stem cell types for emerging therapies.

Stored cells can benefit not just your baby but also siblings, parents, and even grandparents. Americord's 5-compartment storage bags allow for multiple treatments from one collection, offering greater flexibility compared to the standard two-compartment bags used by others in the industry.

Americord combines these versatile plans with top-tier certifications to guarantee quality and safety.

Accreditation and FDA-Approved Treatments

Americord is fully AABB-accredited, which sets the highest standards for cord blood collection, processing, and storage. This accreditation ensures compliance with strict quality protocols, making your stored cells eligible for FDA-approved treatments and clinical trials under the Regenerative Medicine Advanced Therapy (RMAT) designation.

Currently, Americord provides access to over 80 FDA-approved treatments for conditions such as leukemias, lymphomas, and anemias. To back their commitment to quality, Americord offers a $110,000 Cord Blood Quality Guarantee. If your stored cells fail to engraft during treatment, the company will cover the cost of an alternative stem cell source. This level of assurance safeguards your family's investment for the long term.

Conclusion

Cord blood expansion has opened doors for treatments that were once limited to children, making them accessible for adults as well. With the FDA-approved Omisirge, it's now possible to expand cord blood to therapeutic doses suitable for adults. This means your baby's cord blood could potentially help multiple family members battling serious illnesses like leukemia, lymphoma, or sickle cell disease.

Americord's CryoMaxx™ processing and advanced storage system take this a step further. CryoMaxx™ not only preserves stem cells but also optimizes them for future clinical use. The specialized 5-compartment storage bags allow for portions of the sample to be utilized across multiple treatments, ensuring this precious resource remains available for your family's long-term health needs.

These advancements aren't just technical - they represent a meaningful step forward for family health. With regenerative medicine projected to impact 1 in 3 people during their lifetime and over 45,000 cord blood transplants performed globally, banking your baby's stem cells is a proactive choice. In fact, the chance of needing a stem cell transplant by age 70 is approximately 1 in 217.

"With the confidence of the technologies and processes we are providing to families who want to store stem cells from their newborn... we are excited to offer the highest quality guarantee in the industry." - Martin Smithmyer, CEO, Americord

Since collection at birth is a one-time opportunity, Americord offers flexible payment plans starting at $145 per month for 24 months. Plus, the $110,000 Cord Blood Quality Guarantee ensures your investment is protected if engraftment fails. There's never been a better time to consider the benefits of cord blood banking.

FAQs

Does expanded cord blood work as well as a matched adult donor transplant?

Expanded cord blood transplants are showing encouraging progress, though they haven't yet reached the effectiveness of perfectly matched adult donor transplants. Developments like omidubicel and Omisirge™ have significantly improved survival rates and shortened recovery times, particularly for adult recipients. While these advancements are helping close the gap, matched adult donor transplants still set the standard for immune recovery and long-term success. Clinical trials are actively working to refine and advance expanded cord blood technology even further.

How do doctors decide if one expanded cord blood unit is enough for an adult?

Doctors evaluate whether a single expanded cord blood unit is enough for an adult by examining the cell dose. They primarily look at the total nucleated cell (TNC) count and CD34+ cell count to ensure these meet the thresholds necessary for successful engraftment. If the required cell dose isn't met, multiple units might be combined to achieve the desired levels.

Can my baby’s banked cord blood be used for multiple treatments later?

Advances in cord blood expansion technologies now make it possible for a single collection of your baby’s banked cord blood to be used for multiple treatments. These advancements boost the number of stem cells available, allowing for treatment of different conditions or repeated use over a lifetime. This development adds even more long-term value to cord blood banking for families.